2019
DOI: 10.1186/s13041-019-0525-5
|View full text |Cite
|
Sign up to set email alerts
|

Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease

Abstract: Alzheimer’s disease (AD) is an aging-related neurological disorder characterized by synaptic loss and dementia. Wnt/β-catenin signaling is an essential signal transduction pathway that regulates numerous cellular processes including cell survival. In brain, Wnt/β-catenin signaling is not only crucial for neuronal survival and neurogenesis, but it plays important roles in regulating synaptic plasticity and blood-brain barrier integrity and function. Moreover, activation of Wnt/β-catenin signaling inhibits amylo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
150
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 204 publications
(164 citation statements)
references
References 183 publications
0
150
0
1
Order By: Relevance
“…The Wnt/β-catenin signaling pathway has been considered a potential therapeutic target in preventing cell death for an extensive amount of time [ 18 , 40 , 41 ]. The down-regulation of Wnt ligands and increased antagonistic activity have been observed in neurodegenerative and excitotoxic disorders [ 42 , 43 , 44 ].…”
Section: Discussionmentioning
confidence: 99%
“…The Wnt/β-catenin signaling pathway has been considered a potential therapeutic target in preventing cell death for an extensive amount of time [ 18 , 40 , 41 ]. The down-regulation of Wnt ligands and increased antagonistic activity have been observed in neurodegenerative and excitotoxic disorders [ 42 , 43 , 44 ].…”
Section: Discussionmentioning
confidence: 99%
“…In turn, Aβ was identified to increase osteoclast activation and bone resorption [ 81 ]. Thus, targeting of Aβ plaques may evolve as a promising therapeutic approach to prevent cognitive decline and bone loss in patients with AD [ 82 ].…”
Section: Clinical Observationsmentioning
confidence: 99%
“…Therefore, the inhibition of sclerostin was proposed as a therapeutic approach in the treatment of bone loss [ 349 ], which led to the development and approval in the US and Europe of the monoclonal sclerostin-antibody Romosozumab for severe osteoporosis [ 350 , 351 , 352 , 353 ]. In the brain, Wnt/β-catenin signaling is essential for neurogenesis, neuronal survival, synaptic plasticity, BBB integrity [ 82 ] and further associated with the pathophysiology of AD [ 354 ]. As SOST /sclerostin is expressed by several other tissues in physiological and pathogenic conditions [ 355 ], additional studies are required to elucidate whether pharmacologic inhibition of sclerostin may also affect Wnt/β-catenin signaling in the brain [ 8 ].…”
Section: Molecular Bases Of Brain-bone Crosstalkmentioning
confidence: 99%
“…Paraquat exposure altered the levels of the Wnt pathway genes in mouse neural progenitor cells [106], rotenone impaired Wnt signaling in a Drosophila PD model [107] and Deltamethrin also reduced Wnt signaling pathway genes in zebrafish's development of swim bladder [108]. Wnt signaling is known to be impaired in AD [109][110][111], and activation of the Wnt/β-catenin signaling pathway represses BACE-1 expression [112]. Activation of Wnt signaling has been shown to rescue memory loss and improves synaptic dysfunction in APP/PS1 AD transgenic mice [113,114].…”
Section: Enhancement Of Aβ and Tau Expression Modification And Clearmentioning
confidence: 99%